Proteomic risk markers for coronary heart disease and stroke: Validation and mediation of randomized trial hormone therapy effects on these diseases

Genome Medicine

Volumn 5, Issue 12, 2013, Pages

  Prentice, Ross L ^a   Zhao, Shanshan ^a   Johnson, Melissa ^a   Aragaki, Aaron ^a   Hsia, Judith ^b   Jackson, Rebecca D ^c   Rossouw, Jacques E ^d   Manson, JoAnn E ^e   Hanash, Samir M ^f  

^a Fred Hutchinson Cancer Research Center   (United States)

^b ASTRAZENECA   (United Kingdom)

^c OHIO STATE UNIVERSITY   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; COMPLEMENT FACTOR D; ESTROGEN; GESTAGEN; HEMOPEXIN; OROSOMUCOID; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; THROMBOSPONDIN 1;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; RISK ASSESSMENT; THERAPY EFFECT; VALIDATION STUDY;

EID: 84891034769     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm517     Document Type: Article

References (41)

1. King HC, Hoyert DL, Xu JQ, Murphy SL. Deaths: Final Data for 2005. National Vital Statistics Reports 2008, 56. Hyattsville, MD: National Center for Health Statistics.
2. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665. 10.1136/bmj.b1665, 2684577, 19454737.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1307. 10.1056/NEJM199511163332001, 7566020, West of Scotland Coronary Prevention Study Group.
4. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207. 10.1056/NEJMoa0807646, 18997196, JUPITER Study Group.
5. Gordon T, Kannel WB. Multiple risk function for predicting coronary heart disease: the concept, accuracy, and application. Am Heart J 1982, 103:1031-1039. 10.1016/0002-8703(82)90567-1, 7044082.
6. D'Agostino RB, Grundy S, Sullivan LM, Wilson P, for the CHD Risk Prediction Group Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001, 286:180-187. 10.1001/jama.286.2.180, 11448281, for the CHD Risk Prediction Group.
7. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991, 22:312-318. 10.1161/01.STR.22.3.312, 2003301.
8. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. Stroke 1994, 25:40-43. 10.1161/01.STR.25.1.40, 8266381.
9. Chambless LE, Heiss G, Shahar E, Earp MJ, Toole J. Prediction of ischemic stroke risk in the atherosclerosis risk in communities study. Am J Epidemiol 2004, 160:259-269. 10.1093/aje/kwh189, 15257999.
10. Kim HC, Greenland P, Rossouw JE, Manson JE, Cochrane BB, Lasser NL, Limacher MC, Lloyd-Jones DM, Margolis KL, Robinson JG. Multimarker prediction of coronary heart disease risk. J Am Coll Cardiol 2010, 55:2080-2091. 10.1016/j.jacc.2009.12.047, 20447530.
11. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women's Health Initiative Investigators Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003, 349:523-534. 10.1056/NEJMoa030808, 12904517, Women's Health Initiative Investigators.
12. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R, Women's Health Initiative Investigators Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative. Arch Intern Med 2006, 166:357-365. 10.1001/archinte.166.3.357, 16476878, Women's Health Initiative Investigators.
13. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ, WHI Investigators Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: A randomized trial. JAMA 2003, 289:2673-2684. 10.1001/jama.289.20.2673, 12771114, WHI Investigators.
14. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR, Torner J, WHI Investigators Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006, 113:2425-2434. 10.1161/CIRCULATIONAHA.105.594077, 16702472, WHI Investigators.
15. Faca V, Coram M, Phanstiel D, Glukhova V, Zhang Q, Fitzgibbon M, McIntosh M, Hanash S. Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. J Proteome Res 2006, 5:2009-2018. 10.1021/pr060102+, 16889424.
16. The Women's Health Initiative Study Group Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998, 19:61-109. The Women's Health Initiative Study Group.
17. Prentice RL, Paczesny SJ, Aragaki A, Amon LM, Chen L, Pitteri SJ, McIntosh M, Wang P, Busald Buson T, Hsia J, Jackson RD, Rossouw JE, Manson JE, Johnson K, Eaton C, Hanash SM. Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling. Genome Med 2010, 2:48-60. 10.1186/gm169, 2923740, 20667078.
18. Rossouw JE, Cushman M, Greenland P, Lloyd-Jones DM, Bray P, Kooperberg C, Pettinger M, Robinson J, Hendrix S, Hsia J. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease in the Women's Health Initiative trials of hormone therapy. Arch Intern Med 2008, 168:2245-2253. 10.1001/archinte.168.20.2245, 2726792, 19001202.
19. Kooperberg C, Cushman M, Hsia J, Robinson JG, Aragaki AK, Lynch JK, Band AE, Johnson KC, Kuller LH, Beresford SAA, Rodriguez B. Can biomarkers identify women at increased stroke risk? The Women's Health Initiative hormone trials. PLoS Clin Trials 2007, 2:e28. 10.1371/journal.pctr.0020028, 1891725, 17571161.
20. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, Johnson KC, Proulx-Burns L, Pastore L, Criqui M, Daugherty S, WHI Morbidity and Mortality Committee Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 2003, 13:122-128. WHI Morbidity and Mortality Committee.
21. Rauch A, Bellew M, Eng J, Fitzgibbon M, Holzman T, Hussey P, Igra M, Maclean B, Lin CW, Detter A, Fang R, Faca V, Gafken P, Zhang H, Whiteaker J, States D, Hanash S, Paulovich A, McIntosh MW. Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res 2006, 5:112-121. 10.1021/pr0503533, 16396501.
22. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B (Methodological) 1995, 57:289-300.
23. Katayama H, Pacznesny S, Prentice RL, Aragaki A, Faca VM, Pitteri SJ, Zhang Q, Wang H, Silva M, Kennedy J, Rossouw J, Jackson R, Hsia J, Chlebowski R, Manson J, Hanash S. Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med 2009, 1:47.1-47.16.
24. Pitteri SJ, Hanash SM, Aragaki A, Amon L, Chen L, Busald Buson T, Paczesny S, Katayama H, Wang H, Johnson MM, Zhang Q, McIntosh M, Wang P, Kooperberg C, Rossouw JE, Jackson R, Manson JE, Hsia J, Liu S, Martin L, Prentice RL. Postmenopausal estrogen and progestin effects on the serum proteome. Genome Med 2009, 1:121.1-121.14.
25. Prentice RL, Pyke R. Logistic disease incidence models and case-control studies. Biometrika 1979, 66:403-412.
26. Polat H, Yeksan M, Dalmaz M, Kaptanoglu B, Koşar A, Akkuş I. Serum amyloid A protein levels in haemodialysis patients. Nephrol Dial Transplant 1996, 11:1492-1493.
27. Saijo Y, Utsugi M, Yoshioka E, Horikawa N, Sato T, Gong Y, Kishi R. Relationship of B2-Microglobulin to arterial stiffness in Japanese subjects. Hypertens Res 2005, 28:505-511. 10.1291/hypres.28.505, 16231756.
28. Wilson AM, Kimura E, Harada RK, Nair N, Narasimhan B, Meng X-Y, Zhang F, Beck KR, Olin JW, Fung ET, Cooke JP. B2-Microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation 2007, 116:1396-1403. 10.1161/CIRCULATIONAHA.106.683722, 17724262.
29. Liabeuf S, Lenglet A, Desjardins L, Neirynck N, Glorieux G, Lemke H-D, Vanholder R, Diouf M, Choukroun G, Massy ZA, on behalf of the European Uremic Toxin Work Group (EUTox) Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int 2012, 82:1297-1303. 10.1038/ki.2012.301, 22895515, on behalf of the European Uremic Toxin Work Group (EUTox).
30. Amighi J, Hoke M, Mlekusch W, Schlager O, Exner M, Haumer M, Pernicka E, Koppensteiner R, Minar E, Rumpold H, Schillinger M, Wagner O. Beta 2 microglobulin and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. Stroke 2011, 42:1826-1833. 10.1161/STROKEAHA.110.600312, 21546482.
31. Shinkai S, Chaves PHM, Fujiwara Y, Watanabe S, Shibata H, Yoshida H, Suzuki T. B2-Microglobulin for risk stratification of total mortality in the elderly population. Comparison with Cystatin C and C-Reactive Protein. Arch Intern Med 2008, 168:200-206. 10.1001/archinternmed.2007.64, 18227369.
32. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol 2006, 64:355-365.
33. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum Insulin-like Growth Factor I (IGF-1) and IGF-Binding Protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004, 89:114-120. 10.1210/jc.2003-030967, 14715837.
34. Hsiao LL, Dangong F, Yoshida T, Hong R, Jensen RV, Misra J, Dillon W, Lee KF, Clark KE, Haverty P, Weng Z, Mutter GL, Frosch MP, Macdonald ME, Milford EL, Crum CP, Bueno R, Pratt RE, Mahadevappa M, Warrington JA, Stephanoupoulos G, Gullans SR. A compendium of dene expression in normal human tissues. Physiol Genomics 2001, 7:97-104.
35. McLaughlin JN, Mazzoni MR, Cleator JH, Earls L, Perdigoto AL, Brooks JD, Muldowney JAS, Vaughan DE, Hamm HE. Thrombin modulates the expression of a set of genes including thrombospondin-1 in human microvascular endothelial cells. J Biol Chem 2005, 280:22172-22180. 10.1074/jbc.M500721200, 15817447.
36. Russo VC, Gluckman PD, Feldman EL, Werther GA. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev 2005, 26:916-943. 10.1210/er.2004-0024, 16131630.
37. Kooijman R, Sarre S, Michotte Y, De Keyser J. Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke?. Stroke 2009, 40:e83-e88. 10.1161/STROKEAHA.108.528356, 19197073.
38. Johnsen SP, Hundborg HH, Sorensen HT, Orskov H, Tjonneland A, Overvad K, Jorgensen JOL. Insulin-like Growth Factor (IGF) I, -II, and IGF Binding Protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab 2005, 90:5937-5941. 10.1210/jc.2004-2088, 16131586.
39. Denti L, Annoni V, Cattadori E, Salvagnini MA, Visioli S, Merli MF, Corradi F, Ceresini G, Valenti G, Hoffman AR, Ceda GP. Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. Am J Med 2004, 117:312-317. 10.1016/j.amjmed.2004.02.049, 15336580.
40. Bondanelli M, Ambrosio MR, Onofri A, Bergonzoni A, Lavezzi S, Zatelli MC, Valle D, Basaglia N, degli Uberti EC. Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. J Clin Endocrinol Metab 2006, 91:3928-3934. 10.1210/jc.2006-1040, 16882751.
41. Li RC, Saleem S, Zhen G, Cao W, Zhuang H, Lee J, Smith A, Altruda F, Tolosano E, Dore S. Heme-hemopexin complex attenuates neuronal cell death and stroke damage. J Cereb Blood Flow Metab 2009, 29:953-964. 10.1038/jcbfm.2009.19, 19277051.